Sincalide

CHEMBL1121 Phase 4 Approuvé Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1143.3 g/mol
LogP
-2.6
Phase
4

Sincalide is a synthetic C-terminal octapeptide fragment of cholecystokinin (CCK) used diagnostically to stimulate gallbladder contraction for cholescintigraphy and to assess pancreatic exocrine function. By binding to CCK receptors in the gallbladder smooth muscle and pancreatic acinar cells, it mimics endogenous CCK-induced contraction and enzyme secretion. It enables dynamic assessment of gallbladder ejection fraction and pancreatic secretory capacity in nuclear medicine and GI function tests.

Masse moléculaire

1143,3000 g/mol

LogP

-2,60

TPSA

486,00 Ų

Règle des 5 de Lipinski

Non conforme

Mécanisme d'action

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O

InChI

InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1

Molecular Formula

C49H62N10O16S3

HBD / HBA

13 / 19

Liaisons Rotatives

33

Atomes Lourds

78

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Sincalide is a synthetic C-terminal octapeptide fragment of cholecystokinin (CCK) used diagnostically to stimulate gallbladder contraction for cholescintigraphy and to assess pancreatic exocrine function. By binding to CCK receptors in the gallbladder smooth muscle and pancreatic acinar cells, it mimics endogenous CCK-induced contraction and enzyme secretion. It enables dynamic assessment of gallbladder ejection fraction and pancreatic secretory capacity in nuclear medicine and GI function tests.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Sincalide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1121. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9833444. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.